Given all the recent changes in the HTA area – the adoption of the Cabinet of Ministers of Ukraine resolution “On Approval of the Procedure for Conducting State Health Technology Assessment” and the Guideline “State Health Technology Assessment for Medicinal Products” – it is very important to know how to adapt to them.
That is why, understanding the need for appropriate clarifications, experts of the HTA Department launched the practice of training sessions for all interested parties. The first of them took place in April 2021. And now there are new seminars on the guiding Guideline on state HTA.
This time, the comprehensive training “HTA – a Tool for Assessing the Value of a Medical Technology” was held for employees of “AstraZeneca Ukraine”. The speakers were Oresta Piniazhko, Director of the HTA Department, Alona Masheiko, Head of the Unit for Economic Efficiency Assessment of Medicinal Products, and Iryna Romanenko, Head of the Unit for Clinical Efficacy Assessment of Medicinal Products.
During the training, the most relevant issues were covered on the following topics:
- What is HTA and why is it important?
In this block, Oresta Piniazhko provided definitions of the basic concepts of HTA and explained the role of HTA in the healthcare system and in the processes of assessment, appraisal and decision-making. Participants also learned why HTA is important for pharmaceutical policy, the public and patients.
- Best HTA practices
In the second block, Oresta Piniazhko presented the basics of exemplary HTA, the basic HTA model and the stages of conducting HTA in Ukraine in line with leading international experience.
- HTA in Ukraine: areas of implementation and methodological recommendations for dossier preparation.
This block was practice-oriented. During the training, Iryna Romanenko and Alona Masheiko gave participants an understanding of the methodological foundations for developing a model HTA dossier in accordance with the requirements of the Resolution and the Guideline.
- Master class: Modeling.
During the fourth block, participants will gain practical skills in modeling. Namely, a step-by-step algorithm and methodology for building a state transition model / Markov model for analyzing the cost-effectiveness of medicinal products.
AstraZeneca Ukraine became the first company to enable its employees to delve into the methodology of preparing dossiers in accordance with the requirements of the Resolution and the Guideline.
As Oresta Piniazhko, Head of the HTA Department, noted after the trainings, “Direct communication between companies and the body authorized to conduct state HTA in Ukraine is the key to high-quality HTA and a guarantee of improved access for the population of Ukraine to effective and cost-effective medicines. Therefore, the HTA Department will continue to remain open to communication with stakeholders and will continue training activities for all interested parties.”
We thank all participants for the fruitful discussion and interest.
